GSK gets CDSCO panel okay to conduct study on antineoplastic drug Belantamab Mafadotin
New Delhi: In a significant development, GSK Pharmaceuticals ( India) has got approval from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organization (CDSCO) to conduct the Phase 2a clinical trials for the antineoplastic agent Belantamab Mafodotin intravenous solution.
This nod came in line with the condition that the study sites must have an ophthalmologist as Co-Investigator or Sub-Investigator. Furthermore, the expert panel stated that in the event of an adverse event, the study participant(s) should be followed by the study eye doctor for the duration of the study or until the AE is resolved.
This came in the wake of the protocol presented by the drug major, GSK Pharmaceuticals, in the presence of an Ophthalmology expert, for the phase 2a clinical trials (DREAMM 14), study protocol no. 209628, version-01 dated 21st January 2022.
Belantamab Mafadotin is an antineoplastic agent used for the treatment of relapsed and refractory multiple myeloma. It works by slowing or stopping the growth of cancer cells. Belantamab Mafodotin is the latest advance in immunotherapy for multiple myeloma.
Belantamab Mafadotinwas granted FDA approval on August 5, 2020.
At the 120th SEC meeting for Oncology and Haematology, held at CDSCO on March 9th, 2022, the committee thoroughly examined the study protocol presented by GSK Pharmaceuticals Ltd.
After detailed deliberation, the committee recommended the grant of permission to conduct the study with the following conditions:
1) The study sites must have Ophthalmologist as Co-Investigator or Sub-Investigator.
2) In case of an adverse event, the study participant(s) should be followed up to full length or till the resolution of AE by the study Ophthalmologist.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.